Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 1;21(23):6992-5.
doi: 10.1016/j.bmcl.2011.09.124. Epub 2011 Oct 5.

Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond

Affiliations

Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond

Patrick Carberry et al. Bioorg Med Chem Lett. .

Abstract

We have developed a novel F-18 prosthetic ligand named fluoro-PEG-benzaldehyde (FPBA) 1. [(18)F]-FPBA 1 is formed in situ from its radiolabeled precursor [(18)F]6. Compound 6 is efficiently synthesized in four steps starting from commercially available 6-bromo-3-pyridine carbaldehyde 2. [(18)F]-FPBA was evaluated as a prosthetic ligand to radiolabel three cyclic peptides bearing an aminooxy functional group at the N-terminus position. Acetal [(18)F]6 is purified by either solid-phase extraction (SPE) or reverse-phase HPLC with the overall radiochemical yields (RCY) and radiochemical purity (RCP) in very close agreement. The SPE purification process has the advantage of shorter reaction times (71-87 min for entire reaction sequence), while the use of the reverse-phase HPLC purification process allows the use of up to fifty times less of the expensive synthetic peptides (~ 50 nmol) in the oxime coupling reaction. We have demonstrated an efficient methodology in the production of [(18)F]-FPBA 1 and demonstrated its use as a prosthetic ligand for the labeling of peptides possessing an aminooxy functional group.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Novel prosthetic ligand [18F]-fluoro-PEG-benzaldehyde ([18F]-FPBA) 1.
Figure 2
Figure 2
Peptides 7, 8, and 9. AOAC-Tyr-Asp-Cys3-Hyp-Tyr(3-Cl)-Gly-Leu-Cys8-Tyr-Ile-OH, disulfide bond: 3 → 8 (7); AOAC-Arg-Hyp-Cys3-Asp-Tyr(3-Cl)-Tyr(3-Cl)-Gly-Thr-Cys8-Phe-Asp-OH, disulfide bond: 3 → 8 (8); AOAC-Leu-Hyp-Cys3-Asp-Tyr(3-Cl)-Tyr(3-Cl)-Gly-Thr-Cys9-Leu-Asp-OH, disulfide bond: 3 → 9 (9).
Scheme 1
Scheme 1
Synthetic pathway for the preparation of ligand 6. Reagents and conditions: (i) ethylene glycol, p-TsOH, benzene, reflux (98 %); (ii) triethylene glycol, Cs2CO3, DMF, microwave, 150 °C, 50 min (61 %); (iii) p-TsCl, Et3N, DMAP, CH2Cl2 (82 %); (iv) TBAF.H2O, THF, reflux (57 %).
Scheme 2
Scheme 2
General coupling between ligand 6 and peptides 7, 8, and 9. Reagents and conditions: (i) peptide 7, 8, or 9, TFA, EtOH/H2O, 70 °C, 30 min.
Scheme 3
Scheme 3
Radiolabeling of ligand [18F]6. Reagents and conditions: (i) K[222]18F, K2CO3, ACN, 110 °C, 10 min (RCY = 71 ± 2 %; RCP = 99 ± 1 %; n = 3, for SPE purification).
Scheme 4
Scheme 4
General coupling between ligand [18F]6 and peptides [18F]7-ox, [18F]8-ox, and [18F]9-ox. Reagents and conditions: (i) TFA, EtOH/H2O, 70 °C, 2 min, then peptide 7, 8, or 9, EtOH/H2O, 70 °C, 30 min.

References

    1. Tolmachev V, Stone-Elander S. Biochem Biophys Acta, Gen Subjects. 2010;1800:487. - PubMed
    1. Cherry SR. J Clin Pharmacol. 2001;41:482. - PubMed
    1. Ametamey SM, Honer M, Schubiger PA. Chem Rev. 2008;108:1501. - PubMed
    1. Mach RH, Schwarz SW. PET Clinics. 2010;5:131. - PubMed
    1. Kuhnast B, Dolle F. Curr Radiopharm. 2010;3:174.

Publication types

LinkOut - more resources